Interpretation of the key points of "Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries"_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

WANG Peiyu ^1,2 , HUANG Qi ¹ , WANG Shaodong ² , CHEN Xiankai ³ , ZHANG Ruixiang ³ , ZHAO Jia ¹ ,  QIU Mantang ² ,  LI Yin ³ ,  LI Xiangnan ¹

1. Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, P. R. China;
2. Thoracic Oncology Institute/Department of Thoracic Surgery, Peking University People's Hospital, Beijing, 100044, P. R. China;
3. Department of Thoracic Surgical Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College, National Cancer Center/Cancer Hospital, Beijing, 100021, P. R. China;

Corresponding author：

QIU Mantang, Email: qiumantang@163.com; LI Yin, Email: Liyin_thorax@aliyun.com; LI Xiangnan, Email: lxn-2000@163.com

Keywords：

Cancer; global cancer burden; cancer incidence; cancer mortality

DOI：

10.7507/1007-4848.202405013

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

"Global cancer statistics 2022" based on the latest GLOBCAN data from the International Agency for Research on Cancer (IARC) was recently released, providing a systematic analysis of the incidence and mortality of 36 types of cancer across 185 countries worldwide. The international burden of cancer is expected to continue to increase over the next 30 years, posing a severe public health and social challenge for many countries, including China. This article offers a key point interpretation of the "Global cancer statistics 2022", focusing on the evolution of cancer epidemiology and future development trends. The aim is to broaden the international perspective on cancer prevention and treatment, with the hope of providing reference and guidance for cancer prevention and treatment efforts in our country.

Citation： WANG Peiyu, HUANG Qi, WANG Shaodong, CHEN Xiankai, ZHANG Ruixiang, ZHAO Jia, QIU Mantang, LI Yin, LI Xiangnan. Interpretation of the key points of "Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries". Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2024, 31(7): 933-954. doi: 10.7507/1007-4848.202405013 Copy

1.	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA, 2024, 74(3): 229-263 .
2.	Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the Human Development Index (2008–2030): A population-based study. Lancet Oncol, 2012, 13(8): 790-801.
3.	Bray F, Laversanne M, Weiderpass E, et al. The ever‐increasing importance of cancer as a leading cause of premature death worldwide. Cancer, 2021, 127(16): 3029-3030.
4.	Chen S, Cao Z, Prettner K, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol, 2023, 9(4): 465.
5.	International Agency for Research on Cancer. Global Cancer Observatory. URL: https://gco.iarc.who.int. Accessed on 2024-04-05.
6.	Global Burden of Disease 2019 Cancer Collaboration. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 Cancer Groups from 2010 to 2019: A systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol, 2022, 8(3): 420-444.
7.	López-Otín C, Pietrocola F, Roiz-Valle D, et al. Meta-hallmarks of aging and cancer. Cell Metabolism, 2023, 35(1): 12-35.
8.	Anczuków O, Airhart S, Chuang JH, et al. Challenges and opportunities for modeling aging and cancer. Cancer Cell, 2023, 41(4): 641-645.
9.	United Nations. Standard country or area codes for statistical use (M49). URL: https://unstats.un.org/unsd/methodology/m49/. Accessed on 2024-04-05.
10.	United Nations. Human Development Report 2021–22. URL: https://hdr.undp.org/content/human-development-report-2021-22. Accessed on 2024-04-08.
11.	García-Tizón Larroca S, Amor Valera F, Ayuso Herrera E, et al. Human Development Index of the maternal country of origin and its relationship with maternal near miss: A systematic review of the literature. BMC Pregnancy Childbirth, 2020, 20(1): 224.
12.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA, 2021, 71(3): 209-249.
13.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA, 2018, 68(6): 394-424.
14.	Matulewicz RS, Sherman S, Bjurlin MA. Smoking cessation and cancer survivorship. JAMA, 2020, 324(14): 1475.
15.	Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol, 2006, 7(2): 149-156.
16.	Iyengar NM, Gucalp A, Dannenberg AJ, et al. Obesity and cancer mechanisms: Tumor microenvironment and inflammation. J Clin Oncol, 2016, 34(35): 4270-4276.
17.	Turner MC, Andersen ZJ, Baccarelli A, et al. Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations. CA, 2020, 70(6): 460-479.
18.	Keum N, Giovannucci E. Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol, 2019, 16(12): 713-732.
19.	Dixon-Suen SC, Lewis SJ, Martin RM, et al. Physical activity, sedentary time and breast cancer risk: A Mendelian randomisation study. Br J Sports Med, 2022, 56(20): 1157-1170.
20.	Wang YH, Li JQ, Shi JF, et al. Depression and anxiety in relation to cancer incidence and mortality: A systematic review and meta-analysis of cohort studies. Mol Psychiatry, 2020, 25(7): 1487-1499.
21.	Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Nat Cancer Center, 2024, 4(1): 47-53.
22.	Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016. J Nat Cancer Center, 2022, 2(1): 1-9 .
23.	Zhang Y, Vaccarella S, Morgan E, et al. Global variations in lung cancer incidence by histological subtype in 2020: A population-based study. Lancet Oncol, 2023, 24(11): 1206-1218.
24.	Wang P, Wang S, Sun Z, et al. Systemic inflammation influences the prognosis of patients with radically resected non‐small cell lung cancer and correlates with the immunosuppressive microenvironment. Int J Cancer, 2023, 153(4): 826-842.
25.	Organisation for Economic Cooperation and Development (OECD). Health at a glance 2021: OECD indicators. Smoking among adults. URL: https://www.oecd-ilibrary.org/sites/611b5b35-en/index.html?itemId=/content/component/611b5b35-en. Accessed on 2024-04-11.
26.	Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. Thyroid cancer incidence trends by histology in 25 countries: A population-based study. Lancet Diabetes Endocrinol, 2021, 9(4): 225-234.
27.	Vaccarella S, Franceschi S, Bray F, et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. NEJM, 2016, 375(7): 614-617.
28.	Bray F. Transitions in human development and the global cancer burden. World Cancer Report 2014. WHO Press, 2014: 42-55.
29.	Fidler MM, Soerjomataram I, Bray F. A global view on cancer incidence and national levels of the human development index. Int J Cancer, 2016, 139(11): 2436-2446.
30.	Thun M, Peto R, Boreham J, et al. Stages of the cigarette epidemic on entering its second century. Tobacco Control, 2012, 21(2): 96-101.
31.	Wéber A, Morgan E, Vignat J, et al. Lung cancer mortality in the wake of the changing smoking epidemic: A descriptive study of the global burden in 2020 and 2040. BMJ Open, 2023, 13(5): e065303.
32.	Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer, 2001: S4-S66.
33.	Alonso R, Piñeros M, Laversanne M, et al. Lung cancer incidence trends in Uruguay 1990–2014: An age-period-cohort analysis. Cancer Epidemiol, 2018, 55: 17-22.
34.	Jha P. Avoidable global cancer deaths and total deaths from smoking. Nat Rev Cancer, 2009, 9(9): 655-664.
35.	World Health Organization. WHO report on the global tobacco epidemic, 2023: Protect people from tobacco smoke: executive summary. URL: https://www.who.int/publications/i/item/9789240077485. Accessed on 2024-04-15.
36.	Sansone N, Yong HH, Li L, et al. Perceived acceptability of female smoking in China. Tob Control, 2015, 24 (Suppl 4): iv48-iv54.
37.	Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: Current status and future trends. Nat Rev Clin Oncol, 2023, 20(9): 624-639.
38.	Raaschou-Nielsen O, Andersen ZJ, Beelen R, et al. Air pollution and lung cancer incidence in 17 European cohorts: Prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol, 2013, 14(9): 813-822.
39.	Vineis P, Hoek G, Krzyzanowski M, et al. Air pollution and risk of lung cancer in a prospective study in Europe. Int J Cancer, 2006, 119(1): 169-174.
40.	Hill W, Lim EL, Weeden CE, et al. Lung adenocarcinoma promotion by air pollutants. Nature, 2023, 616(7955): 159-167.
41.	Mu L, Liu L, Niu R, et al. Indoor air pollution and risk of lung cancer among Chinese female non-smokers. Cancer Causes & Control, 2013, 24(3): 439-450.
42.	Gredner T, Mons U, Niedermaier T, et al. Impact of tobacco control policies implementation on future lung cancer incidence in Europe: An international, population-based modeling study. Lancet Reg Health Eur, 2021, 4: 100074.
43.	The National Lung Screening Trial Research Team. Lung cancer incidence and mortality with extended follow-up in the national lung screening trial. J Thorac Oncol, 2019, 14(10): 1732-1742.
44.	de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. NEJM, 2020, 382(6): 503-513.
45.	Torre LA, Islami F, Siegel RL, et al. Global cancer in women: Burden and trends. Cancer Epidemiol Biomarkers Prev, 2017, 26(4): 444-457.
46.	Breen N, A. Cronin K, Meissner HI, et al. Reported drop in mammography. Cancer, 2007, 109(12): 2405-2409.
47.	Breen N, Gentleman JF, Schiller JS. Update on mammography trends. Cancer, 2010, 117(10): 2209-1118.
48.	Wojtyla C, Bertuccio P, Wojtyla A, et al. European trends in breast cancer mortality, 1980–2017 and predictions to 2025. Eur J Cancer, 2021, 152: 4-17.
49.	Joko‐Fru WY, Jedy‐Agba E, Korir A, et al. The evolving epidemic of breast cancer in sub‐Saharan Africa: Results from the African Cancer Registry Network. Int J Cancer, 2020, 147(8): 2131-2141.
50.	Sun K, Lei L, Zheng R, et al. Trends in incidence rates, mortality rates, and age-periodcohort effects of female breast cancer — China, 2003–2017. China CDC Weekly, 2023, 5(15): 340-346.
51.	Torres-Román JS, Ybaseta-Medina J, Loli-Guevara S, et al. Disparities in breast cancer mortality among Latin American women: trends and predictions for 2030. BMC Public Health, 2023, 23(1): 1449.
52.	Heer E, Harper A, Escandor N, et al. Global burden and trends in premenopausal and postmenopausal breast cancer: A population-based study. Lancet Global Health, 2020, 8(8): e1027-e1037.
53.	Duggan C, Trapani D, Ilbawi AM, et al. National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: A population-based analysis. Lancet Oncol, 2021, 22(11): 1632-1642.
54.	Soerjomataram I, Cabasag C, Bardot A, et al. Cancer survival in Africa, Central and South America, and Asia (SURVCAN-3): A population-based benchmarking study in 32 countries. Lancet Oncol, 2023, 24(1): 22-32.
55.	Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast, 2022, 66: 15-23.
56.	World Cancer Research Fund/American Institute for Cancer Research. The Continuous Update Project Expert Report 2018. Diet, nutrition, physical activity and cancer: Colorectal cancer. URL: https://www.wcrf.org/wp-content/uploads/2021/02/Colorectal-cancer-report.pdf. Accessed on 2024-04-16.
57.	Schliemann D, Ramanathan K, Matovu N, et al. The implementation of colorectal cancer screening interventions in low-and middle-income countries: A scoping review. BMC Cancer, 2021, 21(1): 1125.
58.	Shaukat A, Levin TR. Current and future colorectal cancer screening strategies. Nat Rev Gastroenterol Hepatol, 2022, 19(8): 521-531.
59.	Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer, 2009, 116(3): 544-573.
60.	Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: A global overview of existing programmes. Gut, 2015, 64(10): 1637-1649.
61.	Siegel RL, Torre LA, Soerjomataram I, et al. Global patterns and trends in colorectal cancer incidence in young adults. Gut, 2019, 68(12): 2179-2185.
62.	Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut, 2017, 66(4): 683-691.
63.	Spaander MCW, Zauber AG, Syngal S, et al. Young-onset colorectal cancer. Nat Rev Dis Prim, 2023, 9(1): 21.
64.	World Cancer Research Fund International. Prostate Cancer. URL: https://www.wcrf.org/diet‐activity‐and‐cancer/cancertypes/prostate-cancer/. Accessed on 2024-04-18.
65.	Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol, 2020, 77(1): 38-52.
66.	Zhou CK, Check DP, Lortet‐Tieulent J, et al. Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group. Int J Cancer, 2015, 138(6): 1388-1400.
67.	Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol, 2012, 61(6): 1079-1092.
68.	Seraphin TP, Joko-Fru WY, Kamaté B, et al. Rising prostate cancer incidence in sub-saharan africa: A trend analysis of data from the African Cancer Registry Network. Cancer Epidemiol Biomarkers Prev, 2021, 30(1): 158-165.
69.	Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Int Med, 2017, 167(7): 449.
70.	Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: Epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol, 2023, 20(5): 338-349.
71.	Kidd M, Lastovica AJ, Atherton JC, et al. Heterogeneity in the helicobacter pylori vacA and cagA genes: Association with gastroduodenal disease in South Africa? Gut, 1999, 45(4): 499-502.
72.	Martel C, Parsonnet J. Stomach Cancer. In Cancer Epidemiology and Prevention. Thun MJ, Linet MS, Cerhan JR, Haiman C, et al. Chief editors. 4th ed. Oxford University Press: Oxford. 2017: 593-610.
73.	Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: Epidemiology of an unplanned triumph. Epidemiol Rev, 1986, 8: 1-27.
74.	Arnold M, Park JY, Camargo MC, et al. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut, 2020, 69(5): 823-829.
75.	Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling study. EClinicalMedicine, 2022, 47: 101404.
76.	de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. The Lancet Global Health, 2020, 8(2): e180-e190.
77.	Rumgay H, Ferlay J, de Martel C, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer, 2022, 161: 108-118.
78.	London WT, Petrick JL, McGlynn KA. Liver Cancer. In: Thun MJ, Linet MS, Cerhan JR, Haiman C, et al. Chief editors. Cancer Epidemiology and Prevention. 4th ed. Oxford University Press: Oxford. 2017: 635-660.
79.	Prueksapanich P, Piyachaturawat P, Aumpansub P, et al. Liver fluke-associated biliary tract cancer. Gut and Liver, 2018, 12(3): 236-245.
80.	Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978–2012. Int J Cancer, 2019, 147(2): 317-330.
81.	Welzel TM, Mellemkjaer L, Gloria G, et al. Risk factors for intrahepatic cholangiocarcinoma in a low‐risk population: A nationwide case‐control study. Int J Cancer, 2006, 120(3): 638-641.
82.	Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterol, 2020, 159(1): 335-349.
83.	Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. NEJM, 1997, 336(26): 1855-1859.
84.	Florio AA, Ferlay J, Znaor A, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer, 2020, 126(11): 2666-2678.
85.	Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999, 189(1): 12-19.
86.	Herrero R, Murillo R. Cervical cancer. In Cancer Epidemiology and Prevention. Thun MJ, Linet MS, Cerhan JR, Haiman C, et al. Chief editors. 4th ed. Oxford University Press: Oxford. 2017: 925-946.
87.	International Agency for Research on Cancer (IARC). IARC Handbooks of Cancer Prevention. Volume 10. Cervix Cancer Screening. URL: http://www.iarc.fr/en/publications/pdfs-online/prev/handbook10/HANDBOOK10.pdf. Accessed on 2024-04-17.
88.	Singh D, Vignat J, Lorenzoni V, et al. Global estimates of incidence and mortality of cervical cancer in 2020: A baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Global Health, 2023, 11(2): e197-e206.
89.	Li M, Meheus F, Polazzi S, et al. The economic cost of thyroid cancer in France and the corresponding share associated with treatment of overdiagnosed cases. Value in Health, 2023, 26(8): 1175-1182.
90.	Panato C, Vaccarella S, Dal Maso L, et al. Thyroid cancer incidence in India between 2006 and 2014 and impact of overdiagnosis. J Clin Endocrinol Metabol, 2020, 105(8): 2507-2514.
91.	Togawa K, Ahn HS, Auvinen A, et al. Long-term strategies for thyroid health monitoring after nuclear accidents: Recommendations from an expert group convened by IARC. Lancet Oncol, 2018, 19(10): 1280-1283.
92.	Kitahara CM, Schneider AB, Brenner AV. Thyroid Cancer. In: Thun MJ, Linet MS, Cerhan JR, Haiman C, et al. Chief editors. 4th ed. Cancer Epidemiology and Prevention. Oxford University Press: Oxford. 2017: 839-860.
93.	Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body fatness and cancer—Viewpoint of the IARC Working Group. NEJM, 2016, 375(8): 794-798.
94.	Silverman DT, Koutros S, Figueroa JD, et al. Bladder Cancer. In: Thun MJ, Linet MS, Cerhan JR, Haiman C, et al. Chief editors. Cancer Epidemiology and Prevention. 4th ed. Oxford University Press: Oxford. 2017: 977-996.
95.	Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol, 2017, 71(1): 96-108.
96.	Parkin DM, Hämmerl L, Ferlay J, et al. Cancer in Africa 2018: The role of infections. Int J Cancer, 2019, 146(8): 2089-2103.
97.	van Hoogstraten LMC, Vrieling A, van der Heijden AG, et al. Global trends in the epidemiology of bladder cancer: Challenges for public health and clinical practice. Nat Rev Clin Oncol, 2023, 20(5): 287-304.
98.	Teoh JY-C, Huang J, Ko WY-K, et al. Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol, 2020, 78(6): 893-906.
99.	Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol, 2013, 64(4): 639-653.
100.	Miranda-Filho A, Piñeros M, Znaor A, et al. Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control, 2019, 30(5): 489-499.
101.	Shiels MS, Engels EA, Linet MS, et al. The epidemic of non–hodgkin lymphoma in the United States: Disentangling the effect of HIV, 1992–2009. Cancer Epidemiol, Biomarkers Prev, 2013, 22(6): 1069-1078.
102.	Usui Y, Ito H, Katanoda K, et al. Trends in non‐Hodgkin lymphoma mortality rate in Japan and the United States: A population‐based study. Cancer Science, 2023, 114(10): 4073-4080.
103.	McCormack VA, Menya D, Munishi MO, et al. Informing etiologic research priorities for squamous cell esophageal cancer in Africa: A review of setting‐specific exposures to known and putative risk factors. Int J Cancer, 2016, 140(2): 259-271.
104.	Blot WJ, Tarone RE. Esophageal Cancer. In: Thun MJ, Linet MS, Cerhan JR, Haiman C, et al. Chief editors. 4th ed. Cancer Epidemiology and Prevention. Oxford University Press: Oxford. 2017: 579-592.
105.	Arnold M, Laversanne M, Brown LM, et al. Predicting the future burden of esophageal cancer by histological subtype: International trends in incidence up to 2030. Am J Gastroenterol, 2017, 112(8): 1247-1255.
106.	Santucci C, Mignozzi S, Malvezzi M, et al. Global trends in esophageal cancer mortality with predictions to 2025, and in incidence by histotype. Cancer Epidemiol, 2023, 87: 102486.
107.	Carioli G, Malvezzi M, Bertuccio P, et al. European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer. Ann Oncol, 2021, 32(4): 478-487.
108.	Klein AP. Pancreatic cancer epidemiology: Understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol, 2021, 18(7): 493-502.
109.	Miranda-Filho A, Piñeros M, Ferlay J, et al. Epidemiological patterns of leukaemia in 184 countries: A population-based study. Lancet Haematol, 2018, 5(1): e14-e24.
110.	United Nations. Our growing population. URL: https://www.un.org/en/global-issues/population#:~:text=The%20world%20population%20is%20projected,surrounding%20these%20latest%20population%20projections. Accessed on 2024-04-19.
111.	United Nations. Aging. URL: https://www.un.org/en/global-issues/ageing. Accessed on 2024-04-18.

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA, 2024, 74(3): 229-263 .
2. Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the Human Development Index (2008–2030): A population-based study. Lancet Oncol, 2012, 13(8): 790-801.
3. Bray F, Laversanne M, Weiderpass E, et al. The ever‐increasing importance of cancer as a leading cause of premature death worldwide. Cancer, 2021, 127(16): 3029-3030.
4. Chen S, Cao Z, Prettner K, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol, 2023, 9(4): 465.
5. International Agency for Research on Cancer. Global Cancer Observatory. URL: https://gco.iarc.who.int. Accessed on 2024-04-05.
6. Global Burden of Disease 2019 Cancer Collaboration. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 Cancer Groups from 2010 to 2019: A systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol, 2022, 8(3): 420-444.
7. López-Otín C, Pietrocola F, Roiz-Valle D, et al. Meta-hallmarks of aging and cancer. Cell Metabolism, 2023, 35(1): 12-35.
8. Anczuków O, Airhart S, Chuang JH, et al. Challenges and opportunities for modeling aging and cancer. Cancer Cell, 2023, 41(4): 641-645.
9. United Nations. Standard country or area codes for statistical use (M49). URL: https://unstats.un.org/unsd/methodology/m49/. Accessed on 2024-04-05.
10. United Nations. Human Development Report 2021–22. URL: https://hdr.undp.org/content/human-development-report-2021-22. Accessed on 2024-04-08.
11. García-Tizón Larroca S, Amor Valera F, Ayuso Herrera E, et al. Human Development Index of the maternal country of origin and its relationship with maternal near miss: A systematic review of the literature. BMC Pregnancy Childbirth, 2020, 20(1): 224.
12. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA, 2021, 71(3): 209-249.
13. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA, 2018, 68(6): 394-424.
14. Matulewicz RS, Sherman S, Bjurlin MA. Smoking cessation and cancer survivorship. JAMA, 2020, 324(14): 1475.
15. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol, 2006, 7(2): 149-156.
16. Iyengar NM, Gucalp A, Dannenberg AJ, et al. Obesity and cancer mechanisms: Tumor microenvironment and inflammation. J Clin Oncol, 2016, 34(35): 4270-4276.
17. Turner MC, Andersen ZJ, Baccarelli A, et al. Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations. CA, 2020, 70(6): 460-479.
18. Keum N, Giovannucci E. Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol, 2019, 16(12): 713-732.
19. Dixon-Suen SC, Lewis SJ, Martin RM, et al. Physical activity, sedentary time and breast cancer risk: A Mendelian randomisation study. Br J Sports Med, 2022, 56(20): 1157-1170.
20. Wang YH, Li JQ, Shi JF, et al. Depression and anxiety in relation to cancer incidence and mortality: A systematic review and meta-analysis of cohort studies. Mol Psychiatry, 2020, 25(7): 1487-1499.
21. Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Nat Cancer Center, 2024, 4(1): 47-53.
22. Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016. J Nat Cancer Center, 2022, 2(1): 1-9 .
23. Zhang Y, Vaccarella S, Morgan E, et al. Global variations in lung cancer incidence by histological subtype in 2020: A population-based study. Lancet Oncol, 2023, 24(11): 1206-1218.
24. Wang P, Wang S, Sun Z, et al. Systemic inflammation influences the prognosis of patients with radically resected non‐small cell lung cancer and correlates with the immunosuppressive microenvironment. Int J Cancer, 2023, 153(4): 826-842.
25. Organisation for Economic Cooperation and Development (OECD). Health at a glance 2021: OECD indicators. Smoking among adults. URL: https://www.oecd-ilibrary.org/sites/611b5b35-en/index.html?itemId=/content/component/611b5b35-en. Accessed on 2024-04-11.
26. Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. Thyroid cancer incidence trends by histology in 25 countries: A population-based study. Lancet Diabetes Endocrinol, 2021, 9(4): 225-234.
27. Vaccarella S, Franceschi S, Bray F, et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. NEJM, 2016, 375(7): 614-617.
28. Bray F. Transitions in human development and the global cancer burden. World Cancer Report 2014. WHO Press, 2014: 42-55.
29. Fidler MM, Soerjomataram I, Bray F. A global view on cancer incidence and national levels of the human development index. Int J Cancer, 2016, 139(11): 2436-2446.
30. Thun M, Peto R, Boreham J, et al. Stages of the cigarette epidemic on entering its second century. Tobacco Control, 2012, 21(2): 96-101.
31. Wéber A, Morgan E, Vignat J, et al. Lung cancer mortality in the wake of the changing smoking epidemic: A descriptive study of the global burden in 2020 and 2040. BMJ Open, 2023, 13(5): e065303.
32. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer, 2001: S4-S66.
33. Alonso R, Piñeros M, Laversanne M, et al. Lung cancer incidence trends in Uruguay 1990–2014: An age-period-cohort analysis. Cancer Epidemiol, 2018, 55: 17-22.
34. Jha P. Avoidable global cancer deaths and total deaths from smoking. Nat Rev Cancer, 2009, 9(9): 655-664.
35. World Health Organization. WHO report on the global tobacco epidemic, 2023: Protect people from tobacco smoke: executive summary. URL: https://www.who.int/publications/i/item/9789240077485. Accessed on 2024-04-15.
36. Sansone N, Yong HH, Li L, et al. Perceived acceptability of female smoking in China. Tob Control, 2015, 24 (Suppl 4): iv48-iv54.
37. Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: Current status and future trends. Nat Rev Clin Oncol, 2023, 20(9): 624-639.
38. Raaschou-Nielsen O, Andersen ZJ, Beelen R, et al. Air pollution and lung cancer incidence in 17 European cohorts: Prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol, 2013, 14(9): 813-822.
39. Vineis P, Hoek G, Krzyzanowski M, et al. Air pollution and risk of lung cancer in a prospective study in Europe. Int J Cancer, 2006, 119(1): 169-174.
40. Hill W, Lim EL, Weeden CE, et al. Lung adenocarcinoma promotion by air pollutants. Nature, 2023, 616(7955): 159-167.
41. Mu L, Liu L, Niu R, et al. Indoor air pollution and risk of lung cancer among Chinese female non-smokers. Cancer Causes & Control, 2013, 24(3): 439-450.
42. Gredner T, Mons U, Niedermaier T, et al. Impact of tobacco control policies implementation on future lung cancer incidence in Europe: An international, population-based modeling study. Lancet Reg Health Eur, 2021, 4: 100074.
43. The National Lung Screening Trial Research Team. Lung cancer incidence and mortality with extended follow-up in the national lung screening trial. J Thorac Oncol, 2019, 14(10): 1732-1742.
44. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. NEJM, 2020, 382(6): 503-513.
45. Torre LA, Islami F, Siegel RL, et al. Global cancer in women: Burden and trends. Cancer Epidemiol Biomarkers Prev, 2017, 26(4): 444-457.
46. Breen N, A. Cronin K, Meissner HI, et al. Reported drop in mammography. Cancer, 2007, 109(12): 2405-2409.
47. Breen N, Gentleman JF, Schiller JS. Update on mammography trends. Cancer, 2010, 117(10): 2209-1118.
48. Wojtyla C, Bertuccio P, Wojtyla A, et al. European trends in breast cancer mortality, 1980–2017 and predictions to 2025. Eur J Cancer, 2021, 152: 4-17.
49. Joko‐Fru WY, Jedy‐Agba E, Korir A, et al. The evolving epidemic of breast cancer in sub‐Saharan Africa: Results from the African Cancer Registry Network. Int J Cancer, 2020, 147(8): 2131-2141.
50. Sun K, Lei L, Zheng R, et al. Trends in incidence rates, mortality rates, and age-periodcohort effects of female breast cancer — China, 2003–2017. China CDC Weekly, 2023, 5(15): 340-346.
51. Torres-Román JS, Ybaseta-Medina J, Loli-Guevara S, et al. Disparities in breast cancer mortality among Latin American women: trends and predictions for 2030. BMC Public Health, 2023, 23(1): 1449.
52. Heer E, Harper A, Escandor N, et al. Global burden and trends in premenopausal and postmenopausal breast cancer: A population-based study. Lancet Global Health, 2020, 8(8): e1027-e1037.
53. Duggan C, Trapani D, Ilbawi AM, et al. National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: A population-based analysis. Lancet Oncol, 2021, 22(11): 1632-1642.
54. Soerjomataram I, Cabasag C, Bardot A, et al. Cancer survival in Africa, Central and South America, and Asia (SURVCAN-3): A population-based benchmarking study in 32 countries. Lancet Oncol, 2023, 24(1): 22-32.
55. Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast, 2022, 66: 15-23.
56. World Cancer Research Fund/American Institute for Cancer Research. The Continuous Update Project Expert Report 2018. Diet, nutrition, physical activity and cancer: Colorectal cancer. URL: https://www.wcrf.org/wp-content/uploads/2021/02/Colorectal-cancer-report.pdf. Accessed on 2024-04-16.
57. Schliemann D, Ramanathan K, Matovu N, et al. The implementation of colorectal cancer screening interventions in low-and middle-income countries: A scoping review. BMC Cancer, 2021, 21(1): 1125.
58. Shaukat A, Levin TR. Current and future colorectal cancer screening strategies. Nat Rev Gastroenterol Hepatol, 2022, 19(8): 521-531.
59. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer, 2009, 116(3): 544-573.
60. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: A global overview of existing programmes. Gut, 2015, 64(10): 1637-1649.
61. Siegel RL, Torre LA, Soerjomataram I, et al. Global patterns and trends in colorectal cancer incidence in young adults. Gut, 2019, 68(12): 2179-2185.
62. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut, 2017, 66(4): 683-691.
63. Spaander MCW, Zauber AG, Syngal S, et al. Young-onset colorectal cancer. Nat Rev Dis Prim, 2023, 9(1): 21.
64. World Cancer Research Fund International. Prostate Cancer. URL: https://www.wcrf.org/diet‐activity‐and‐cancer/cancertypes/prostate-cancer/. Accessed on 2024-04-18.
65. Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol, 2020, 77(1): 38-52.
66. Zhou CK, Check DP, Lortet‐Tieulent J, et al. Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group. Int J Cancer, 2015, 138(6): 1388-1400.
67. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol, 2012, 61(6): 1079-1092.
68. Seraphin TP, Joko-Fru WY, Kamaté B, et al. Rising prostate cancer incidence in sub-saharan africa: A trend analysis of data from the African Cancer Registry Network. Cancer Epidemiol Biomarkers Prev, 2021, 30(1): 158-165.
69. Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Int Med, 2017, 167(7): 449.
70. Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: Epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol, 2023, 20(5): 338-349.
71. Kidd M, Lastovica AJ, Atherton JC, et al. Heterogeneity in the helicobacter pylori vacA and cagA genes: Association with gastroduodenal disease in South Africa? Gut, 1999, 45(4): 499-502.
72. Martel C, Parsonnet J. Stomach Cancer. In Cancer Epidemiology and Prevention. Thun MJ, Linet MS, Cerhan JR, Haiman C, et al. Chief editors. 4th ed. Oxford University Press: Oxford. 2017: 593-610.
73. Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: Epidemiology of an unplanned triumph. Epidemiol Rev, 1986, 8: 1-27.
74. Arnold M, Park JY, Camargo MC, et al. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut, 2020, 69(5): 823-829.
75. Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling study. EClinicalMedicine, 2022, 47: 101404.
76. de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. The Lancet Global Health, 2020, 8(2): e180-e190.
77. Rumgay H, Ferlay J, de Martel C, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer, 2022, 161: 108-118.
78. London WT, Petrick JL, McGlynn KA. Liver Cancer. In: Thun MJ, Linet MS, Cerhan JR, Haiman C, et al. Chief editors. Cancer Epidemiology and Prevention. 4th ed. Oxford University Press: Oxford. 2017: 635-660.
79. Prueksapanich P, Piyachaturawat P, Aumpansub P, et al. Liver fluke-associated biliary tract cancer. Gut and Liver, 2018, 12(3): 236-245.
80. Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978–2012. Int J Cancer, 2019, 147(2): 317-330.
81. Welzel TM, Mellemkjaer L, Gloria G, et al. Risk factors for intrahepatic cholangiocarcinoma in a low‐risk population: A nationwide case‐control study. Int J Cancer, 2006, 120(3): 638-641.
82. Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterol, 2020, 159(1): 335-349.
83. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. NEJM, 1997, 336(26): 1855-1859.
84. Florio AA, Ferlay J, Znaor A, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer, 2020, 126(11): 2666-2678.
85. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999, 189(1): 12-19.
86. Herrero R, Murillo R. Cervical cancer. In Cancer Epidemiology and Prevention. Thun MJ, Linet MS, Cerhan JR, Haiman C, et al. Chief editors. 4th ed. Oxford University Press: Oxford. 2017: 925-946.
87. International Agency for Research on Cancer (IARC). IARC Handbooks of Cancer Prevention. Volume 10. Cervix Cancer Screening. URL: http://www.iarc.fr/en/publications/pdfs-online/prev/handbook10/HANDBOOK10.pdf. Accessed on 2024-04-17.
88. Singh D, Vignat J, Lorenzoni V, et al. Global estimates of incidence and mortality of cervical cancer in 2020: A baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Global Health, 2023, 11(2): e197-e206.
89. Li M, Meheus F, Polazzi S, et al. The economic cost of thyroid cancer in France and the corresponding share associated with treatment of overdiagnosed cases. Value in Health, 2023, 26(8): 1175-1182.
90. Panato C, Vaccarella S, Dal Maso L, et al. Thyroid cancer incidence in India between 2006 and 2014 and impact of overdiagnosis. J Clin Endocrinol Metabol, 2020, 105(8): 2507-2514.
91. Togawa K, Ahn HS, Auvinen A, et al. Long-term strategies for thyroid health monitoring after nuclear accidents: Recommendations from an expert group convened by IARC. Lancet Oncol, 2018, 19(10): 1280-1283.
92. Kitahara CM, Schneider AB, Brenner AV. Thyroid Cancer. In: Thun MJ, Linet MS, Cerhan JR, Haiman C, et al. Chief editors. 4th ed. Cancer Epidemiology and Prevention. Oxford University Press: Oxford. 2017: 839-860.
93. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body fatness and cancer—Viewpoint of the IARC Working Group. NEJM, 2016, 375(8): 794-798.
94. Silverman DT, Koutros S, Figueroa JD, et al. Bladder Cancer. In: Thun MJ, Linet MS, Cerhan JR, Haiman C, et al. Chief editors. Cancer Epidemiology and Prevention. 4th ed. Oxford University Press: Oxford. 2017: 977-996.
95. Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol, 2017, 71(1): 96-108.
96. Parkin DM, Hämmerl L, Ferlay J, et al. Cancer in Africa 2018: The role of infections. Int J Cancer, 2019, 146(8): 2089-2103.
97. van Hoogstraten LMC, Vrieling A, van der Heijden AG, et al. Global trends in the epidemiology of bladder cancer: Challenges for public health and clinical practice. Nat Rev Clin Oncol, 2023, 20(5): 287-304.
98. Teoh JY-C, Huang J, Ko WY-K, et al. Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol, 2020, 78(6): 893-906.
99. Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol, 2013, 64(4): 639-653.
100. Miranda-Filho A, Piñeros M, Znaor A, et al. Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control, 2019, 30(5): 489-499.
101. Shiels MS, Engels EA, Linet MS, et al. The epidemic of non–hodgkin lymphoma in the United States: Disentangling the effect of HIV, 1992–2009. Cancer Epidemiol, Biomarkers Prev, 2013, 22(6): 1069-1078.
102. Usui Y, Ito H, Katanoda K, et al. Trends in non‐Hodgkin lymphoma mortality rate in Japan and the United States: A population‐based study. Cancer Science, 2023, 114(10): 4073-4080.
103. McCormack VA, Menya D, Munishi MO, et al. Informing etiologic research priorities for squamous cell esophageal cancer in Africa: A review of setting‐specific exposures to known and putative risk factors. Int J Cancer, 2016, 140(2): 259-271.
104. Blot WJ, Tarone RE. Esophageal Cancer. In: Thun MJ, Linet MS, Cerhan JR, Haiman C, et al. Chief editors. 4th ed. Cancer Epidemiology and Prevention. Oxford University Press: Oxford. 2017: 579-592.
105. Arnold M, Laversanne M, Brown LM, et al. Predicting the future burden of esophageal cancer by histological subtype: International trends in incidence up to 2030. Am J Gastroenterol, 2017, 112(8): 1247-1255.
106. Santucci C, Mignozzi S, Malvezzi M, et al. Global trends in esophageal cancer mortality with predictions to 2025, and in incidence by histotype. Cancer Epidemiol, 2023, 87: 102486.
107. Carioli G, Malvezzi M, Bertuccio P, et al. European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer. Ann Oncol, 2021, 32(4): 478-487.
108. Klein AP. Pancreatic cancer epidemiology: Understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol, 2021, 18(7): 493-502.
109. Miranda-Filho A, Piñeros M, Ferlay J, et al. Epidemiological patterns of leukaemia in 184 countries: A population-based study. Lancet Haematol, 2018, 5(1): e14-e24.
110. United Nations. Our growing population. URL: https://www.un.org/en/global-issues/population#:~:text=The%20world%20population%20is%20projected,surrounding%20these%20latest%20population%20projections. Accessed on 2024-04-19.
111. United Nations. Aging. URL: https://www.un.org/en/global-issues/ageing. Accessed on 2024-04-18.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Interpretation of the key points of "Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries"

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content